TR200401735T4 - Giraz önleyicileri ve bunların kullanımları - Google Patents

Giraz önleyicileri ve bunların kullanımları

Info

Publication number
TR200401735T4
TR200401735T4 TR2004/01735T TR200401735T TR200401735T4 TR 200401735 T4 TR200401735 T4 TR 200401735T4 TR 2004/01735 T TR2004/01735 T TR 2004/01735T TR 200401735 T TR200401735 T TR 200401735T TR 200401735 T4 TR200401735 T4 TR 200401735T4
Authority
TR
Turkey
Prior art keywords
gyrase inhibitors
compounds
oxazole
pyrazole
thiazole
Prior art date
Application number
TR2004/01735T
Other languages
English (en)
Inventor
Charifson Paul
Stamos Dean
Badia Michael
Grillot Anne-Laure
Ronkin Steven
Trudeau Martin
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of TR200401735T4 publication Critical patent/TR200401735T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Özet: Mevcut bulus, A halkasinin, bir tiyazol, oksazol, imidazol veya pirazol ve ikame edicilerin de, spesifikasyonda tarif edildigi gibi oldugu formül (I)'e ait bilesiklere ve bunlarin farmasötik açidan kabul gören tuzlariyla ilgilidir. Bilesikler, bakteriyel giraz aktivitesini önlerler ve bu nedenle de memelilerdeki bakteriyel enfeksiyonlarin tedavisinde faydalanir.
TR2004/01735T 2000-01-18 2001-01-16 Giraz önleyicileri ve bunların kullanımları TR200401735T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17667100P 2000-01-18 2000-01-18
US25433100P 2000-12-08 2000-12-08

Publications (1)

Publication Number Publication Date
TR200401735T4 true TR200401735T4 (tr) 2004-08-23

Family

ID=26872470

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01735T TR200401735T4 (tr) 2000-01-18 2001-01-16 Giraz önleyicileri ve bunların kullanımları

Country Status (23)

Country Link
US (2) US6608087B1 (tr)
EP (1) EP1251848B1 (tr)
JP (1) JP2003520233A (tr)
CN (1) CN1230166C (tr)
AR (1) AR027518A1 (tr)
AT (1) ATE269701T1 (tr)
AU (1) AU782883B2 (tr)
BR (1) BR0107713A (tr)
CA (1) CA2397686A1 (tr)
CO (1) CO5261612A1 (tr)
DE (1) DE60103974T2 (tr)
DK (1) DK1251848T3 (tr)
EA (1) EA005680B1 (tr)
ES (1) ES2222336T3 (tr)
HK (1) HK1053984B (tr)
MX (1) MXPA02007134A (tr)
MY (1) MY133572A (tr)
NZ (1) NZ520628A (tr)
PT (1) PT1251848E (tr)
SI (1) SI1251848T1 (tr)
TR (1) TR200401735T4 (tr)
TW (1) TWI287449B (tr)
WO (1) WO2001052845A1 (tr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
IL160327A0 (en) * 2001-08-13 2004-07-25 Janssen Pharmaceutica Nv 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
US20080234132A1 (en) * 2004-11-19 2008-09-25 Laurence Coquin Microcin B17 Analogs And Methods For Their Preparation And Use
NZ561613A (en) 2005-02-18 2010-12-24 Astrazeneca Ab Antibacterial piperidine derivatives
CA2642754A1 (en) * 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
EP3025653B1 (en) 2006-06-21 2021-06-16 Cook Biotech Incorporated Fistula grafts useful for treating gastrointestinal fistulae
US20100234348A1 (en) * 2006-08-04 2010-09-16 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
BRPI0817897A2 (pt) * 2007-11-02 2019-09-24 Methylgene Inc composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2009227013B2 (en) * 2008-03-21 2013-01-10 Novartis Ag Novel heterocyclic compounds and uses therof
AU2009272033B2 (en) * 2008-07-17 2011-10-13 Asahi Kasei Pharma Corporation Nitrogenated heterocyclic compound
US8536185B2 (en) * 2008-09-22 2013-09-17 Cayman Chemical Company, Incorporated Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
AU2010341229A1 (en) * 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
MX2013001660A (es) 2010-08-11 2013-06-03 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
CN102911173A (zh) * 2012-11-08 2013-02-06 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
MX2016010057A (es) 2014-02-03 2017-04-27 Spero Gyrase Inc Compuestos antibacterianos.
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057431A1 (en) 2017-03-24 2018-09-27 Taisho Pharmaceutical Co., Ltd. 2(1h)-quinolinone derivative
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
WO2018213185A1 (en) 2017-05-17 2018-11-22 Drexel University Rela inhibitors for biofilm disruption
WO2020048949A1 (en) 2018-09-03 2020-03-12 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP4263503A1 (en) 2020-12-17 2023-10-25 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
NL2033609B1 (en) * 2022-11-24 2024-05-30 Innes John Centre DNA Gyrase Inhibitors
AU2023418987A1 (en) * 2022-12-30 2025-07-03 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
EP4663242A1 (en) * 2024-06-11 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Targeting the energy coupling factor (ecf) transporters as novel antimicrobial target

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
RU2173147C2 (ru) * 1996-05-09 2001-09-10 Санкио Компани Лимитед Применение производных 1-метилкарбопенема, антибактериальная в отношении helicobacter pylori композиция, содержащая в качестве активного ингредиента 1-метилкарбопенемовые производные и способ профилактики или лечения инфекционных заболеваний

Also Published As

Publication number Publication date
ES2222336T3 (es) 2005-02-01
DE60103974T2 (de) 2005-06-30
EA200200769A1 (ru) 2002-12-26
CO5261612A1 (es) 2003-03-31
MXPA02007134A (es) 2003-03-27
US6930116B2 (en) 2005-08-16
AU3094001A (en) 2001-07-31
EP1251848B1 (en) 2004-06-23
HK1053984B (zh) 2006-07-28
EA005680B1 (ru) 2005-04-28
WO2001052845A1 (en) 2001-07-26
US6608087B1 (en) 2003-08-19
AU782883B2 (en) 2005-09-08
HK1053984A1 (en) 2003-11-14
DE60103974D1 (de) 2004-07-29
BR0107713A (pt) 2002-11-19
SI1251848T1 (en) 2004-12-31
NZ520628A (en) 2004-05-28
US20040024030A1 (en) 2004-02-05
CA2397686A1 (en) 2001-07-26
PT1251848E (pt) 2004-10-29
TWI287449B (en) 2007-10-01
JP2003520233A (ja) 2003-07-02
AR027518A1 (es) 2003-04-02
CN1230166C (zh) 2005-12-07
DK1251848T3 (da) 2004-10-18
MY133572A (en) 2007-11-30
CN1400898A (zh) 2003-03-05
ATE269701T1 (de) 2004-07-15
EP1251848A1 (en) 2002-10-30

Similar Documents

Publication Publication Date Title
TR200401735T4 (tr) Giraz önleyicileri ve bunların kullanımları
ECSP003699A (es) Inhibidores de fab i
TR199902203T2 (tr) Fernesil transferaz engelleyici, N-veya C-baglantili imidazoller ile ikame edilmis 1,8-anele kinolinon türevleri.
JO2646B1 (en) New differentiated cyclic compounds as beta - lactam inhibitors
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
AU9309898A (en) Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
BR0013237A (pt) Fenil oxazolidinonas substituìdas heterobiciclicas antibacterianas
CY1106958T1 (el) Ν-αλκυλο-4-μεθυλεναμινο-3-υδροξυ-2-πυριδονες ως αντιμικροβιακα
JO2256B1 (en) Renin inhibitors
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
BR0011121A (pt) Compostos antibacterianos
ATE433963T1 (de) Fab-i inhibitoren
SE0301232D0 (sv) Novel use
SE9701304D0 (sv) Compounds
TR200001330T2 (tr) Oksazolidinon türevleri ve farmasötik terkipler
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
SE9803518D0 (sv) Novel compounds
BG108498A (en) New derivatives of oxazolidinones as antibacterial agents
BR0305708A (pt) Derivados de benzimidazol para o tratamento de disfunção sexual
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
ATE339424T1 (de) 3-substituierte 7-alkylidene-3-cephem-4- carbonsäuren als beta-lactamase inhibitoren
HRP20050517B1 (hr) N-sulfonil-4-metilenamino-3-hidroksi-2-piridoni kao antimikrobni lijekovi
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
DE69910738D1 (de) Fungizide zusammensetzung enthaltend ein n-benzoyl-n'-phenyl-harnstoff derivat